BridgeBio Pharma to Participate in May Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced participation in several investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced participation in several investor conferences. Key events include the Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel on May 18 at 2:30 PM ET, and multiple sessions on May 24, including H. C. Wainwright Global Investment Conference at 7:00 AM ET, UBS Global Healthcare Conference at 11:30 AM ET, and J. P. Morgan West Coast Investor Day at 12:00 PM ET. For more details, visit the BridgeBio Investors page.
Details
News Market Reaction – BBIO
The recorded move for BBIO in the trading session of this news was +10.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:
- Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel, Virtual: Wednesday, May 18th at 2:30 pm ET
- H. C. Wainwright Global Investment Conference, Virtual: Tuesday, May 24th at 7:00 am ET
- UBS Global Healthcare Conference, New York, NY: Tuesday, May 24th at 11:30 am ET
- J. P. Morgan West Coast Investor Day, San Francisco, CA: Tuesday, May 24th at 12:00 pm ET
To access more details on BridgeBio’s presentations, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Grace Rauh
Grace.rauh@bridgebio.com
(917) 232-5478
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.